146 patents
Page 4 of 8
Utility
Flow Cytometry for Monitoring Histone H3 Methylation Status
5 Aug 21
The present disclosure relates to methods of detecting histone epigenetic modifications and compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
Christopher PLESCIA
Filed: 22 Dec 20
Utility
Methods of Synthesizing Substituted Purine Compounds
29 Jul 21
The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Edward J. OLHAVA
Filed: 18 Sep 20
Utility
Crystalline Compounds and Methods of Making the Same
22 Jul 21
Provided herein are methods for making a crystalline form of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide and related products, compositions and treatment methods.
Marinus Jacobus VERWIJS, David Jon AM ENDE, Stephen Richard ANDERSON, Andrew Paul George BEEVERS, Mark Kenneth BREAULT, Stephen Richard TUDHOPE, Jamie Ross WOLSTENHULME
Filed: 1 Apr 21
Utility
Methods of Using EHMT2 Inhibitors In Immunotherapies
15 Jul 21
The present disclosure relates to methods and compositions for treating immune-mediated diseases.
Kat COSMOPOULOS, Elayne PENEBRE
Filed: 18 Oct 18
Utility
Method for Treating Cancer
15 Jul 21
The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
Heike KEILHACK, Sarah K. KNUTSON
Filed: 21 Dec 20
Utility
Aryl-or heteroaryl-substituted benzene compounds
6 Jul 21
The present invention relates to aryl- or heteroaryl-substituted benzene compounds.
Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
Filed: 22 Oct 19
Utility
Amine-substituted Aryl or Heteroaryl Compounds
1 Jul 21
The present disclosure relates to amine-substituted aryl or heteroaryl compounds.
John Emmerson CAMPBELL, Kenneth William DUNCAN, Megan Alene FOLEY, Darren Martin HARVEY, Kevin Wayne KUNTZ, James Edward John MILLS, Michael John MUNCHHOF
Filed: 20 Nov 20
Utility
Smyd Inhibitors
1 Jul 21
Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
Filed: 1 May 20
Utility
Combination therapy for treating cancer
8 Jun 21
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Heike Keilhack, Roberto Pili
Filed: 6 Sep 19
Utility
CARM1 Inhibitors and Uses Thereof
27 May 21
Richard Chesworth, Oscar Miguel Moradei, Gideon Shapiro, Lei Jin, Robert E. Babine
Filed: 18 Mar 20
Utility
Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor
13 May 21
Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide.
Kevin Wayne KUNTZ, Kuan-Chun HUANG, Hyeong Wook CHOI, Kristen SANDERS, Steven MATHIEU, Arani CHANDA, Francis FANG
Filed: 25 Sep 20
Utility
Method of Treating Malignant Rhabdoid Tumor of the Ovary (Mrto)/small Cell Cancer of the Ovary of the Hypercalcemic Type(sccoht) with an EZH2 Inhibitor
29 Apr 21
The disclosure provides a method of treating a malignant rhabdoid tumor in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor.
Heike KEILHACK
Filed: 3 Sep 20
Utility
Combination Therapy for Treating Cancer
8 Apr 21
The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
Christine KLAUS, Maria Alejandra RAIMONDI
Filed: 30 Mar 18
Utility
Methods of synthesizing substituted purine compounds
6 Apr 21
The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Edward James Olhava
Filed: 18 Mar 19
Utility
Arginine Methyltransferase Inhibitors and Uses Thereof
18 Mar 21
Richard Chesworth, Lorna Helen Mitchell, Gideon Shapiro, Kerren Kalai Swinger
Filed: 27 Aug 20
Utility
Method for treating cancer
16 Mar 21
The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.
Heike Keilhack
Filed: 18 Jun 19
Utility
Substituted Benzene Compounds
4 Mar 21
The present invention relates to substituted benzene compounds.
Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
Filed: 9 Jul 20
Utility
Combination Therapy for Treating Cancer
4 Mar 21
The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount.
Maria Alejandra RAIMONDI, Dorothy BRACH
Filed: 5 Sep 18
Utility
Method for Treating Cancer
4 Mar 21
The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
Heike KEILHACK, Brett TRUITT, Yuta SUZUKI, Tsukasa MURASE, Futoshi SHIKATA
Filed: 20 Aug 20
Utility
Combination Therapy for Treating Cancer
25 Feb 21
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Heike KEILHACK, Sarah Kathleen KNUTSON, Kevin Wayne KUNTZ
Filed: 5 Aug 20